Evaluation of monodansylcadaverine for effects on tumor growth.
D000614:Aminocaproates / Q000627:therapeutic use; D000818:Animals; D002103:Cadaverine / Q000008:administration & dosage / Q000627:therapeutic use; D003619:Dansyl Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D007939:Leukemia L1210 / Q000401:mortality / Q000517:prevention & control*; D051379:Mice; D008807:Mice, Inbred BALB C; D008811:Mice, Inbred DBA; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000201:enzymology / Q000401:mortality / Q000517:prevention & control; D010954:Plasmacytoma / Q000201:enzymology / Q000401:mortality / Q000517:prevention & control*; D013449:Sulfonamides / Q000008:administration & dosage; D014184:Transplantation, Homologous
D000614:Aminocaproates; D003619:Dansyl Compounds; D013449:Sulfonamides; D002103:Cadaverine